Angiogenesis inhibitors are the mainstay of the treatment of advanced renal cell carcinoma. However, the treatment algorithm is rapidly evolving driven by the approval of novel agents, including the first market entry of an immune checkpoint inhibitor. Several areas of high unmet need—notably, treatments for the adjuvant and first-line patient populations—offer significant commercial opportunity for innovative agents. Multiple immune checkpoint inhibitor combination therapies are in late-phase development in the first-line setting and have the potential to significantly alter the treatment paradigm. This content provides insight on how treatment options for advanced renal cell carcinoma are likely to change over the 2015-2025 forecast period. It also analyzes the current and future sales potential of drugs already in the market and those expected to be approved for advanced renal cell carcinoma.
The first immune checkpoint inhibitor for renal cell carcinoma was approved in late 2015. How will the treatment algorithm of renal cell carcinoma change as a result of this approval? Which other immune checkpoint inhibitors are promising in renal cell carcinoma? For which patient populations are immune checkpoint inhibitors most likely to be approved? What will be the impact of immune checkpoint inhibitors on the renal cell carcinoma market?
In 2016, two novel small-molecule angiogenesis inhibitors entered the renal cell carcinoma market for use in previously treated patients. How will these agents change the treatment pathways for previously treated advanced/metastatic renal cell carcinoma? How will they compete with current angiogenesis inhibitors and emerging agents from other drug classes?
Immune checkpoint inhibitor combination therapies are a prominent feature of the late-phase development pipeline for renal cell carcinoma and are all positioned in the lucrative first-line setting. How will established drug classes compete with these emerging therapies in an increasingly fragmented market landscape? How do the various combination regimens differ? How will the safety and tolerability of these regimens affect their uptake?
Sutent has provided survival benefits in the adjuvant patient population, revitalizing interest in this area of high unmet need. Other angiogenesis inhibitors are also in late-phase development in the high-risk adjuvant patient population. How large is the adjuvant therapy market in renal cell carcinoma? How will it be affected by the potential approvals of angiogenesis inhibitors? What will be the uptake of these agents in the adjuvant setting?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 21 country-specific interviews with key opinion leaders and 212 country-specific surveys with community oncologists treating renal cell carcinoma.
Epidemiology: Incidence by disease stage (stage I, stage II, stage III, stage IV) for renal cell carcinoma; progressed incidence of stage IV renal cell carcinoma.
Population segments in market forecast: Adjuvant (stage I-III), first-line advanced/metastatic, second-line advanced/metastatic, third-line advanced/metastatic, fourth-line advanced/metastatic.
Emerging therapies: Phase II: 18 drugs; Phase III: 7.